Recombinant bacterial lipoproteins as vaccine candidates. (2nd December 2015)

• Record Type: Journal Article
• Authors: Leng, Chih-Hsiang; Liu, Shih-Jen; Chen, Hsin-Wei; Chong, Pele
• Is Part Of: Expert review of vaccines. Volume 14:Number 12(2015)
• Page Start: 1623
• Page End: 1632
• Publication Date: 2015-12-02
• Subjects: adjuvant -- Braun's lipoproteins -- Clostridium difficile-associated diseases -- cervical cancer -- dengue virus -- lipobox leader sequences -- meningococcal group B -- subunit vaccine -- synthetic adjuvant PAMCSK4 -- Toll-like receptor agonist; Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• DOI: 10.1586/14760584.2015.1091732
• Languages: English
• ISSNs: 1476-0584

Abstract

Abstract : Recombinant bacterial lipoproteins (RLP) with built-in immuno-stimulating properties for novel subunit vaccine development are reviewed. This platform technology offers the following advantages: easily converts antigens into highly immunogenic RLP using a fusion sequence containing lipobox; the lipid moiety of RLP is recognized as the danger signals in the immune system through the Toll-like receptor 2, so both innate and adaptive immune responses can be induced by RLP; serves as an efficient and cost-effective bioprocess for producing RLP in Escherichia coli and the feasibility and safety of this core platform technology has been successfully demonstrated in animal model studies including meningococcal group B subunit vaccine, dengue subunit vaccine, novel subunit vaccine against Clostridium difficile -associated diseases and HPV-based immunotherapeutic vaccines.